Welcome To The Resverlogix HUB On AGORACOM

**Apabetalone (RVX-208) Currently Being Tested in a Phase 3 BETonMACE Trial and a Phase 2 Kidney Trial is Planned for 2017**

Free
AGORACOM NEWS FLASH

NEW CLIENT ALERT!!!

AGORACOM Welcomes BetterU Education Corp. (TSX-V:BTRU)

  • Connecting global education with the Indian Marketplace
  • $30 million marketing investment deal signed
  • Ability to reach 100 MILLION potential learners each week
  • India expecting to double in online education sales from $20B to $40B this year

CHECK OUT OUR RECENT INTERVIEW!

Betteru large

Hub On AGORACOM / Corporate Profile

Message: Resverlogix Announces Presentation at 9th Annual Biotech Showcase Conference in San Francisco, CA

News Release Issued: Jan 5, 2017 (3:43pm MST)

Resverlogix Announces Presentation at 9th Annual Biotech Showcase Conference in San Francisco, CA

CALGARY, Jan. 5, 2017 /CNW/ - Resverlogix Corp. ("Resverlogix", or the "Company") (TSX:RVX) today announces its participation in the 9th Annual Biotech Showcase Conference during J.P. Morgan week in San Francisco, CA. Mr. Donald J. McCaffrey, President and CEO, will provide a corporate update and overview of recent activities at the conference.

Presentation Details:

Date: January 9th
Time: 2:00pm PT 
Duration: 30 minutes
Location: Room 3 (Ballroom Level) at the Hilton San Francisco Union Square 

Mr. McCaffrey's presentation will be available on the Company website on the Media/Events page immediately prior to the scheduled presentation time. 

To schedule a meeting with senior management in San Francisco during the event, please contact Investor Relations.

About Resverlogix

Resverlogix is developing apabetalone (RVX-208), a first-in-class, small molecule that is a selective BET (bromodomain and extra-terminal) inhibitor. BET bromodomain inhibition is an epigenetic mechanism that can regulate disease-causing genes. Apabetalone is the first and only BET inhibitor selective for the second bromodomain (BD2) within the BET protein called BRD4. This selective inhibition of apabetalone on BD2 produces a specific set of biological effects with potentially important benefits for patients with diseases such as high-risk cardiovascular disease (CVD), diabetes mellitus (DM), chronic kidney disease, Alzheimer's disease, Orphan diseases, and peripheral artery disease, while maintaining a well described safety profile. Apabetalone is the only selective BET bromodomain inhibitor in human clinical trials, currently in a Phase 3 trial BETonMACE in high-risk CVD patients with type 2 DM and low high-density lipoprotein (HDL). 

Resverlogix common shares trade on the Toronto Stock Exchange (TSX:RVX). 

For further information please visit www.resverlogix.com

Follow us on Twitter: @Resverlogix_RVX (https://twitter.com/resverlogix_rvx), or on our blog at http://www.resverlogix.com/blog

For further information please contact:

Investor Relations
Email: 
ir@resverlogix.com
Phone: 403-254-9252

SOURCE Resverlogix Corp.

Share
New Message
Please login to post a reply